Notably, large meta-analyses and collaborative trial datasets have demonstrated no excess risk of severe hypoglycemia, major adverse events, or treatment discontinuation with combination therapy compared with either class alone [11, 28,29,30], supporting the safety and tolerability of combined use in diverse populations
A reduction in fat and weight was also observed (141)
Review Article Abstract Introduction Retatrutide for Treatment of Obesity Retatrutide for Treatment of Type 2 Diabetes Effects of Retatrutide on Cardiovascular Risk Factors Safety of Retatrutide Effect of Retatrutide on Heart Rate Advantages of Retatrutide Limitations of Retatrutide Conclusions and Current Needs References Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes Nasser Mikhail 1* and Soma Wali 2 1* and Soma Wali 2 1 Endocrinology Division, Olive View-UCLA Medical Center, David-Geffen UCLA Medical School, USA 2 Department of Medicine, Olive View-UCLA Medical Center, David-Geffen UCLA Medical School, USA Submission: July 18, 2023
An eligible clinician included ( on a Participation List on any such snapshot date is included in the APM Entity group even if that eligible clinician is not included on that Participation List at one of the prior- or later-listed dates
It is important to understand the distinctions between them to make an informed choice